Showing results (191-200 of 276) with videos related to

Sort By:
Pageof 28
Transplantation|July 17, 2012
Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?Pierre Peterlin, Christophe Leux, Thomas Gastinne, et al.
Annals of the New York Academy of Sciences|August 12, 2005
The murine cardiac 26S proteasome: an organelle awaiting explorationAldrin V Gomes, Chenggong Zong, Ricky D Edmondson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment IntensityFabienne Desmots, Delphine Rossille, Mikael Roussel, et al.
Blood Advances|May 1, 2025
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomasPierre Stephan, Roberta Di Blasi, Louise Roulin, et al.
Cancer Reports (Hoboken, N.J.)|July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trialCarla Casulo, Armando Santoro, Guillaume Cartron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteriaTim M Illidge, Sam Mayes, Ruth Pettengell, et al.
British Journal of Haematology|May 26, 2012
Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du SangEstelle Gimenez, Martine Chauvet, Laetitia Rabin, et al.
Transplantation and Cellular Therapy|February 26, 2022
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell TransplantationMaxime Jullien, Amandine Le Bourgeois, Marianne Coste-Burel, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
Blood|August 10, 2023
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphomaSalomé Decombis, Celine Bellanger, Yannick Le Bris, et al.
Pageof 28